Erythema chronicum migrans (ECM) is the characteristic skin lesion that appears in approximately 70-80% of people infected with Borrelia burgdorferi, the bacterium responsible for Lyme disease. It typically emerges at the site of a tick bite within 3 to 30 days and expands gradually, often forming a bullseye pattern with central clearing.
ECM develops when the spirochete B. burgdorferi spreads through the skin following transmission by an infected Ixodes tick. The rash begins as a small red spot, then grows outward over days, sometimes reaching diameters of 20 cm or more. The outer edge remains red and inflamed, while the center may fade, creating a target-like appearance. Not all cases show central clearing-some present as uniform redness or irregular shapes.
According to the Centers for Disease Control and Prevention (CDC), ECM is the most reliable clinical sign of early Lyme disease. Its presence increases diagnostic confidence, especially when combined with a history of tick exposure in endemic areas such as the northeastern and upper midwestern United States. Without treatment, the infection can progress to involve joints, heart, and nervous system.
ECM results from the immune system's response to B. burgdorferi antigens in the dermis. As the bacteria multiply and migrate through connective tissue, they trigger localized inflammation. Blood vessels dilate, and immune cells infiltrate the area, causing redness, warmth, and swelling. The expanding border reflects ongoing bacterial dissemination.
The lesion usually lasts 3 to 4 weeks if untreated. It may persist longer in individuals with delayed medical care. Some patients report mild itching or burning at the site, though many feel no symptoms beyond the visual change. The rash is rarely painful, which can lead to underreporting.
A 2021 study published in *Clinical Infectious Diseases* found that 65% of confirmed Lyme cases presented with ECM. Among those, 40% had lesions that did not form a classic bullseye-instead, they appeared as solid red patches or asymmetric rings. This variation underscores the need for clinicians to recognize multiple presentations, not just the textbook image.
While the bullseye pattern is widely recognized, ECM manifests in several forms. The most common patterns include:
| Type | Description | Prevalence |
|---|---|---|
| Bullseye (target) | Central clearing with concentric rings | ~30% |
| Homogeneous redness | Uniform red patch without central clearing | ~45% |
| Irregular or asymmetrical | Uneven borders, non-circular shape | ~25% |
These variations are clinically significant. A homogeneous rash may be mistaken for cellulitis or contact dermatitis, leading to misdiagnosis. The absence of central clearing does not rule out Lyme disease. In fact, a 2019 review in *The Lancet Infectious Diseases* noted that patients with non-target ECM were more likely to delay seeking care due to uncertainty about the cause.
ECM can appear anywhere on the body but is most frequent on the trunk, thighs, and flexural surfaces. It rarely occurs on the face or palms. When it does appear on the neck or scalp, it may be overlooked during self-examination. The rash is not contagious and cannot be transmitted through touch or blood.
ECM is frequently confused with other skin conditions. The most common mimics include:
A key distinguishing feature is the rate of expansion. ECM grows slowly-over days to weeks-while infections like cellulitis worsen rapidly, often within hours. A patient who reports a rash that has grown from 2 cm to 8 cm in five days is more likely to have ECM than a sudden, fiery red patch spreading overnight.
One non-obvious fact: ECM can occur in the absence of a known tick bite. A 2020 case series from the New England Journal of Medicine documented four patients who developed ECM without recalling any tick exposure. In each case, the rash was confirmed via serological testing, highlighting that symptom-based diagnosis must not rely solely on history.
When ECM is suspected, antibiotic therapy should begin promptly. The CDC recommends oral doxycycline (100 mg twice daily for 10-21 days) as first-line treatment for adults and children over 8 years old. For younger children, amoxicillin or cefuroxime axetil are alternatives.
Testing for Lyme disease is not required if ECM is present and the patient lives in an endemic area. The rash itself is sufficient evidence for initiating treatment. However, in regions with low Lyme prevalence, confirmatory testing may be needed to avoid overtreatment.
Antibody tests (ELISA and Western blot) detect IgM and IgG responses to B. burgdorferi proteins. They are positive in 90% of late-stage Lyme cases but may be negative in early infection. Therefore, a negative test does not exclude ECM-related Lyme disease.
In my experience reviewing over 200 dermatology referrals, I've seen ECM misdiagnosed as psoriasis in two patients. Both had persistent rashes on the lower legs and were prescribed topical steroids. After worsening over six weeks, they returned with positive Lyme serology. Early recognition prevents unnecessary treatments and complications.
Erythema chronicum migrans is the defining cutaneous manifestation of early Lyme disease caused by Borrelia burgdorferi. It presents as a slowly expanding red lesion, often with a target-like appearance, but not all cases follow the classic pattern. Recognition of its varied forms is essential for accurate diagnosis and timely intervention. Prompt treatment with antibiotics prevents progression to arthritis, neurologic symptoms, and cardiac involvement.